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AIMS: Obesity is a primary contributor to acquired insulin resistance leading to
the development of type 2 diabetes and cardiovascular alterations. The carnitine
derivate, propionyl-L-carnitine (PLC), plays a key role in energy control. Our aim
was to evaluate metabolic and cardiovascular effects of PLC in diet-induced obese
mice.
METHODS: C57BL/6 mice were fed a high-fat diet for 9 weeks and then divided
into two groups, receiving either free- (vehicle-HF) or PLC-supplemented water
(200 mg/kg/day) during 4 additional weeks. Standard diet-fed animals were used
as lean controls (vehicle-ST). Body weight and food intake were monitored.
Glucose and insulin tolerance tests were assessed, as well as the HOMA(IR), the
serum lipid profile, the hepatic and muscular mitochondrial activity and the tissue
nitric oxide (NO) liberation. Systolic blood pressure, cardiac and endothelial
functions were also evaluated.
RESULTS: Vehicle-HF displayed a greater increase of body weight compared to
vehicle-ST that was completely reversed by PLC treatment without affecting food
intake. PLC improved the insulin-resistant state and reversed the increased total
cholesterol but not the increase in free fatty acid, triglyceride and HDL/LDL ratio
induced by high-fat diet. Vehicle-HF exhibited a reduced cardiac output/body
weight ratio, endothelial dysfunction and tissue decrease of NO production, all of
them being improved by PLC treatment. Finally, the decrease of hepatic
mitochondrial activity by high-fat diet was reversed by PLC.
CONCLUSIONS: Oral administration of PLC improves the insulin-resistant state
developed by obese animals and decreases the cardiovascular risk associated to
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